Chad ssert compensation by year
ANI PHARMACEUTICALS Summary Compensation Table · the one fiscal year held| Component | FY2023 |
|---|---|
| Salary | $429,223 |
| Bonus | $0 |
| Stock awards | $1,046,532 |
| Option awards | $0 |
| Non-equity incentive | $413,133 |
| Pension and deferred compensation | $0 |
| All other | $7,355 |
| Total | $1,896,243 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ANI PHARMACEUTICALS INC DEF 14A filed April 5, 2024, accession 0001023024-24-000037, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ANI PHARMACEUTICALS INC filed document, accession 0001023024-24-000037. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2024.
ANI PHARMACEUTICALS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Nikhil Lalwani | President and Chief Executive Officer | $8,078,353 |
| Stephen Carey | Senior Vice President and Chief Financial Officer | $2,576,088 |
| Ori Gutwerg | Senior Vice President, Generics | $1,941,690 |
| Christopher Mutz | Senior Vice President, Head of Rare Disease | $1,914,451 |
| Chad ssert · this page | Senior Vice President, Corporate Development and Strategy | $1,896,243 |
The full ANI PHARMACEUTICALS compensation record
free company briefThis page is one person within ANI PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ANI PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ANI PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.